Dramatic response of metaplastic breast cancer to chemo-immunotherapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology
Link
http://www.nature.com/articles/s41523-017-0011-0.pdf
Reference13 articles.
1. Weigelt, B., Eberle, C., Cowell, C. F., Ng, C. K. & Reis-Filho, J. S. Metaplastic breast carcinoma: more than a special type. Nat. Rev. Cancer 14, 147–148 (2014).
2. Nelson, R. A., Guye, M. L., Luu, T. & Lai, L. L. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann. Surg. Oncol. 22, 24–31, doi: 10.1245/s10434-014-3890-4 (2015).
3. Rayson, D., Adjei, A. A., Suman, V. J., Wold, L. E. & Ingle, J. N. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann. Oncol. 10, 413–419 (1999).
4. Moulder, S. et al. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann. Oncol. 26, 1346–1352, doi: 10.1093/annonc/mdv163 (2015).
5. Joneja, U. et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J. Clin. Pathol. doi: 10.1136/jclinpath-2016-203874 (2016).
Cited by 62 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report;Thoracic Cancer;2024-09
2. Case report: Successful treatment of a rare HER2-positive advanced breast squamous cell carcinoma;Frontiers in Pharmacology;2024-02-22
3. Cáncer de mama metaplásico: a propósito de un caso;Clínica e Investigación en Ginecología y Obstetricia;2024-01
4. Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab;Case Reports in Oncology;2023-10-16
5. A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer;npj Breast Cancer;2023-06-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3